Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, P

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients will b

Related Keywords

United States , Turkey , Mexico , Georgia , India , Thailand , Malaysia , Spain , Germany , Japan , Serbia , Philippines , Brazil , Romania , Jane Chung , Anna Nayun Kim , Samsung Bioepis , Ilsun Hong , Drug Administration , Merck Sharp Dohme Corp , Samsung Bioepis Co Ltd , Ministry Of Food , Product Evaluation Team Leader Of Samsung Bioepis , Committee For Medicinal Products Human Use , European Medicines Agency , Vice President , Product Evaluation Team Leader , Merck Sharp , Drug Safety , Biologics License Application , Medicinal Products , Human Use , Nayun Kim , Phase 3 Clinical Trial , Iopharmaceutical Company , Clinical Trial , Incheon , Korea , Iv Infusion , Vitamin Supplementation ,